Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association
Top Cited Papers
Open Access
- 11 September 2022
- journal article
- research article
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 17 (1) , 19-39
Abstract
No abstract availableKeywords
This publication has 78 references indexed in Scilit:
- The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin‐Associated Musculoskeletal SymptomsClinical Pharmacology & Therapeutics, 2022
- Statin Discontinuation and Cardiovascular Events Among Older People in DenmarkJAMA Network Open, 2021
- The Allied Health Professional’s Role in the Management of Dyslipidemia and Accreditation Council for Clinical Lipidology Certification Program2020
- Shared decision‐making for older adults with cardiovascular diseaseClinical Cardiology, 2019
- Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin‐associated muscle symptoms, under blinded and open‐label conditionsJournal of Cachexia, Sarcopenia and Muscle, 2018
- The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater ReliabilityCardiovascular Drugs and Therapy, 2017
- Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin IntoleranceJAMA, 2016
- Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO StudyCardiovascular Drugs and Therapy, 2005
- The Lipid Research Clinics Coronary Primary Prevention Trial ResultsJAMA, 1984
- Clofibrate and Niacin in Coronary Heart DiseaseJAMA, 1975